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Summary
Background The number of individuals living with dementia is increasing, negatively affecting families, communities, 
and health-care systems around the world. A successful response to these challenges requires an accurate 
understanding of the dementia disease burden. We aimed to present the first detailed analysis of the global prevalence, 
mortality, and overall burden of dementia as captured by the Global Burden of Diseases, Injuries, and Risk Factors 
(GBD) Study 2016, and highlight the most important messages for clinicians and neurologists.
Methods GBD 2016 obtained data on dementia from vital registration systems, published scientific literature and 
surveys, and data from health-service encounters on deaths, excess mortality, prevalence, and incidence from 
195 countries and territories from 1990 to 2016, through systematic review and additional data-seeking efforts. To 
correct for differences in cause of death coding across time and locations, we modelled mortality due to dementia 
using prevalence data and estimates of excess mortality derived from countries that were most likely to code deaths to 
dementia relative to prevalence. Data were analysed by standardised methods to estimate deaths, prevalence, years of 
life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs; computed as the 
sum of YLLs and YLDs), and the fractions of these metrics that were attributable to four risk factors that met GBD 
criteria for assessment (high body-mass index [BMI], high fasting plasma glucose, smoking, and a diet high in sugar-
sweetened beverages).
Findings In 2016, the global number of individuals who lived with dementia was 43·8 million (95% uncertainty interval 
[UI] 37·8–51·0), increased from 20.2 million (17·4–23·5) in 1990. This increase of 117% (95% UI 114–121) contrasted 
with a minor increase in age-standardised prevalence of 1·7% (1·0–2·4), from 701 cases (95% UI 602–815) per 
100 000 population in 1990 to 712 cases (614–828) per 100 000 population in 2016. More women than men had dementia 
in 2016 (27·0 million, 95% UI 23·3–31·4, vs 16.8 million, 14.4–19.6), and dementia was the fifth leading cause of death 
globally, accounting for 2·4 million (95% UI 2·1–2·8) deaths. Overall, 28·8 million (95% UI 24·5–34·0) DALYs were 
attributed to dementia; 6·4 million (95% UI 3·4–10·5) of these could be attributed to the modifiable GBD risk factors 
of high BMI, high fasting plasma glucose, smoking, and a high intake of sugar-sweetened beverages.
Interpretation The global number of people living with dementia more than doubled from 1990 to 2016, mainly due 
to increases in population ageing and growth. Although differences in coding for causes of death and the heterogeneity 
in case-ascertainment methods constitute major challenges to the estimation of the burden of dementia, future 
analyses should improve on the methods for the correction of these biases. Until breakthroughs are made in 
prevention or curative treatment, dementia will constitute an increasing challenge to health-care systems worldwide.
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Introduction
Alzheimer’s disease and other dementias are a major 
and increasing global health challenge, with 40–50 million 
people currently living with dementia.1–3 Care and support 
of patients with dementia has wide-ranging consequences 
for families, health-care systems, and society as a whole.4 
There is growing evidence of risk factors for demen-
tia, which shows that lifestyle and other interventions 
might, if implemented effectively, contribute to delaying 
the onset and reducing the future number of people 
who have dementia.5–9 Changes in risk factor exposures 
might account for several cohort studies documenting a 
reduction in age-specific incidence rates in their study 
populations.3,6,10,11
The Global Burden of Diseases, Injuries, and Risk Factors 
(GBD) Study uses a systematic method to analyse fatal and 
non-fatal health losses to facilitate comparisons across 
countries and diseases. Annual updates of results quantify 
mortality, prevalence, incidence, and non-fatal health losses 
for more than 300 diseases and injuries by age and sex 
from 1990 for 195 countries and territories and many 
subnational locations, such as Mexican states or provinces 
of China. Although other efforts to estimate dementia pre-
valence1,2,12 have used meta-analytic strategies to synthesise 
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the available data, these analyses did not attempt to re-
concile and make the combined best use of different types 
of data on incidence, prevalence, excess mortality, and 
causes of death reported in literature sources, claims 
databases, and vital registration systems. Furthermore, 
GBD assesses the strength of causal evidence for risks and 
includes estimates of attributable disease burden from risk 
factors using a comparative risk assessment framework.
Global data and cross-country comparisons might help 
further current understanding of complex and multi-
factorial diseases such as dementia. The capacity of GBD 
to examine patterns across countries creates a unique 
opportunity to identify populations with different trends 
that in turn could reveal clustered risk or environmental 
factors, providing empirical evidence about factors that 
affect neurodegenerative diseases.4 Such findings could 
provide insights that can supplement and aid ongoing 
research, and also allow estimates of the future effect of 
dementia expected from rapidly ageing populations across 
the world. To facilitate further exploration of these 
patterns, we present an analysis of GBD 2016 data with 
the aim of articulating the key methods, results, and 
limitations pertaining to dementia estimation.
Methods
Overview and data sources
General methods of GBD, including methods for 
calculating the Socio-demographic Index (SDI), a com-
posite indicator combining income per person, educa-
tion, and fertility, can be found in the general methods 
overview (appendix) and in the GBD 2016 overview 
papers.13–16 In this Article, we have highlighted the meth-
ods pertaining to processes specific to the estimation 
of Alzhemier’s disease and other dementias (hereafter 
referred to as dementia).
For the GBD analyses, the reference case definitions 
were either those from the Diagnostic and Statistical 
Manual of Mental Disorders (DSM; DSM-III, DSM-IV, or 
DSM-5), which are used in surveys and cohort studies, or 
those from the International Classification of Diseases 
(ICD; ICD-8, ICD-9, and ICD-10), which are used in vital 
registration and claims data sources.17,18 For GBD analyses 
of dementia, the relevant ICD-9 codes were 290, 291.2, 
291.8, 294, and 331, and the relevant ICD-10 codes were 
F00, F01, F02, F03, G30, and G31. In GBD, for each disease 
a reference case definition was chosen that represents 
the most recent consensus or the most commonly used 
Research in context
Evidence before this study
Over the past decade, there have been substantial research 
efforts to describe the global epidemiology of Alzheimer’s 
disease and other dementias. Other efforts to summarise the 
evidence, including the World Dementia Report, have compiled 
evidence through systematic reviews and meta-analyses, but 
they report only on dementia prevalence by world region. 
The Global Burden of Diseases, Injuries, and Risk Factors (GBD) 
Study has published regular updates of estimates for dementia 
in 195 countries and territories and subnational locations, 
such as the provinces of China and states in countries such as 
Brazil, the USA, and Mexico. However, there has been no 
dedicated and detailed publication of GBD methods and 
estimates for dementia. GBD 2016 estimates for dementia 
incorporated 43 new data sources on the prevalence and 
incidence of dementia, updating a previous review that 
covered 1980 to 2015; new sources were identified through 
a systematic review of English-language articles published in 
PubMed from 23 Jan, 2015, to Oct 7, 2016,with the search terms 
“dementia”[Title/Abstract] AND (“prevalence” OR “incidence”)
[Title/Abstract].
Added value of this study
GBD 2016 added 5-year age groups from ages 80 to 95 years to 
replace the oldest category (≥80 years) used in GBD 2015, 
providing more detailed estimates where the burden from 
dementia was highest. Our report examined more closely the 
methods, results, and limitations specific to Alzheimer’s disease 
and other dementias with the aim of making this information 
more accessible to clinicians and researchers. The data 
informing estimates were heterogeneous, with 230 different 
diagnostic procedures across 237 studies. Over time, the 
global age-standardised prevalence was fairly stable: 
701 cases (95% uncertainty interval [UI] 602–815) per 
100 000 population in 1990 and 712 cases (614–828) per 
100 000 population in 2016, constituting an increase of 1·7% 
(95% UI 1·0–2·4). However, because of population ageing and 
growth, the number of people affected by dementia more than 
doubled since 1990 and almost 44 million prevalent cases were 
estimated globally in 2016. Age-standardised prevalence was 
1·17 (1·17–1·18) times higher in females than in males. We also 
estimated that 22·3% (11·8–35·1) of the total global DALYs due 
to dementia in 2016 could be attributed to the four modifiable  
risk factors that met GBD criteria for assessment (high 
body-mass index, high fasting plasma glucose, a diet high in 
sugar-sweetened beverages, and smoking). 
Implications of all the available evidence
This analysis identified substantial heterogeneity in 
case-ascertainment methods throughout the dementia 
literature, highlighting the need for more consistency in future 
research. Nevertheless, there is no doubt about the striking 
increase in the numbers of individuals living with dementia 
since 1990 due to ageing and population growth. Despite some 
evidence indicating small decreases in age-specific incidence, 
without a major scientific breakthrough the continuation of 
sweeping demographic trends in population ageing and 
growth will lead to further increases in the number of people 
living with dementia. With limited scope for prevention and the 
absence of an effective disease-modifying treatment, the 
burden on caregivers and the parts of health-care systems 
devoted to care of the elderly will continue to increase rapidly.
See Online for appendix
Articles
90 www.thelancet.com/neurology   Vol 18   January 2019
definition. Data based on alternative case definitions were 
adjusted if systematic bias was detected. We included 
237 sources of data from the scientific literature, and 
3 years of medical claims data from the USA. We identified 
176 sources reporting on prevalence, covering 17 of 
21 world regions, and 64 sources on incidence, covering 
ten of 21 world regions (appendix). No input data were 
available for Oceania, central Asia, eastern Europe, or 
southern sub-Saharan Africa.
We could not adjust the data for different study designs 
or case definitions because of the extreme hetero-
geneity in case-ascertainment methods. We identified 
230 different methods of screening and diagnosis in the 
237 scientific literature sources. Data points that had an 
age range of greater than 20 years were split into new 
data points for the 5-year age groups within the age 
range, using the age pattern from the USA as the country 
for which we had the most detailed information.
Natural-history model
We did not use the typical GBD cause of death ensemble 
modelling (CODEm) approach for dementia because we 
noted large inconsistencies between cause of death data 
and prevalence data over time and between countries. 
Data from the US Vital Registration system showed that 
the age-standardised rates of deaths from dementia 
between 1990 and 2016 increased by a factor of five, 
whereas there has been no corresponding increase in 
the prevalence of dementia over the same period.19–21 
Additionally, the highest age-standardised death rates 
were more than 50 times higher than the lowest age-
standardised death rates across different locations for 
2016, possibly indicating that the practice of coding a 
death to dementia as an underlying cause of death has 
not been consistent over time or between countries. To 
adjust for this bias, we jointly modelled cause of death 
and non-fatal outcomes for dementia. We first ran an 
initial cause of death model using CODEm, and an initial 
non-fatal model using DisMod-MR 2.1, the Bayesian 
meta-regression tool used in most non-fatal models for 
GBD.22,23 DisMod-MR 2.1 enforces consistency between 
the different parameters, because incidence determines 
the inflow into the pool of prevalent cases and excess 
mortality determines outflow via death. The rates of 
inflow and outflow then determine the average duration 
of disease. Both DisMod MR 2.1 and CODEm use 
covariates and borrow strength from locations in the 
same region that have data to make estimates for 
locations where there are no input data.
The initial CODEm model included 16 226 site-years of 
data (ie, data for a unique combination of location and 
calendar year). The covariates used in the initial CODEm 
model included diabetes prevalence, mean cholesterol, 
and mean body-mass index (BMI; full list in the 
appendix). The initial DisMod-MR 2.1 model included 
settings of no remission (ie, no cure), and no incidence 
before age 40 years. We also excluded incidence data from 
the model, because data for incidence and prevalence 
were inconsistent. In many locations, the incidence data 
combined with mortality estimates suggested a prevalence 
higher than the available prevalence data, and the model 
fitted above the prevalence data and below the incidence 
data. Because measurement of prevalent cases of de-
mentia probably has less error than measurement of 
incident cases, we decided to exclude incidence data and 
rely on prevalence data.
We let DisMod-MR 2.1 adjust medical claims data to 
correct for under-reporting compared with survey data. 
We used average years of education in the population 
aged 15 years and older and smoking prevalence as 
predictive covariates, because these risk factors for 
dementia have a large evidence base.24,25 From the initial 
model results we identified the locations with high-
quality vital registration systems that most often coded 
to dementia as a cause of death per prevalent case in 
the most recent year of estimates. For GBD 2016, 
these locations were the USA, Finland, Sweden, and 
Puerto Rico. We then used the log-transformed ratio 
between cause-specific mortality and prevalence for these 
locations to run a fixed-effects linear regression with 
dummy variables on 5-year age bins and sex. Because the 
ratio of cause-specific mortality and prevalence is an 
estimate of excess mortality rate, we used the results of 
this regression to predict data inputs for every GBD 
location and all years in a second DisMod-MR 2.1 model. 
As an exception, we retained the 2016 ratios of cause-
specific mortality and prevalence for the four locations 
used in the regression analysis but assumed the 2016 
ratios applied to the whole 1990–2016 period. Otherwise, 
the model included the same assumptions and covariates 
as the initial DisMod-MR 2.1 model. We used the 
prevalence outputs from this model to estimate years 
lived with disability (YLDs). We also used the cause-
specific mortality estimated from this model for our final 
cause-specific mortality results.
YLDs and risk estimation
To derive YLDs for dementia, we first divided dementia 
prevalence into three severity categories. We used data 
from a systematic review of studies reporting on the 
Clinical Dementia Rating Scale (CDR)26 and pooled 
proportions of mild (CDR 1), moderate (CDR 2), and 
severe dementia (CDR 3) in random-effect meta-analyses. 
We did this separately for ages 40–69, 70–79, and 80 years 
or more. For GBD 2016, we included seven studies 
identified through systematic review published from 
1980 to 2015, covering two world regions. To calculate 
YLDs, we multiplied the prevalence at each severity level 
by the corresponding disability weight24 and further 
corrected for comorbidity using a simulation assigning 
all non-fatal outcomes to hypothetical individuals for 
each age group, sex, location, and year.27
We made estimates for high BMI, high fasting plasma 
glucose, smoking (including all smoked tobacco products), 
For the data sources used in the 
analysis see http://ghdx.health 
data.org/gbd-2016/data-input-
sources
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Deaths Prevalence DALYs 
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
Global 2 382 129 
(2 060 410 to 2 777 610)
3·6 
(1·1 to 5·6)
43 835 665 
(37 756 336 to 
51 028 051)
1·7 
(1·0 to 2·4)
28 764 110 
(24 510 789 to 
33 952 387)
2·1 
(0·1 to 3·8)
High SDI 969 191 
(844 580 to 1 104 900)
2·5 
(0·2 to 5·2)
15 164 211 
(13 282 384 to 
17 306 959)
0·3 
(–1·2 to 1·7)
9 886 396 
(8 517 721 to 
11 471 661)
–0·3 
(–2·3 to 2·0)
High-middle SDI 448 457 
(383 293 to 526 151)
4·1 
(–0·6 to 9·1)
8 858 166 
(7 587 609 to 
10 305 640)
8·1 
(6·7 to 10·4)
5 561 354 
(4 692 609 to 
6 539 404)
4·4 
(0·4 to 8·6)
Middle SDI 658 727 
(561 952 to 780 604)
0·9 
(–4·5 to 5·0)
13 200 041 
(11 201 343 to 
15 593 470)
1·5 
(0·7 to 2·3)
8 905 818 
(7 506 192 to 
10 630 061)
0·8 
(–3·4 to 3·7)
Low-middle SDI 246 768 
(206 143 to 300 717)
9·6 
(1·7 to 16·5)
5 348 335 
(4 509 649 to 
6 326 468)
–2·7 
(–3·4 to –2·1)
3 530 640 
(2 942 604 to 
4 280 829)
5·6 
(0·3 to 10·6)
Low SDI 57 730 
(48 159 to 71 752)
8·8 
(2·8 to 15·8)
1 110 454 
(934 598 to 1 315 691)
–3·0 
(–3·9 to –1·9)
844 222 
(696 157 to 1 031 439)
6·0 
(1·5 to 11·0)
High-income North America 260 080 
(233 175 to 288 591)
9·9 
(3·3 to 16·6)
4 347 849 
(3 975 725 to 4 734 147)
–1·6 
(–7·3 to 4·9)
2 688 057 
(2 397 360 to 
3 011 096)
2·5 
(–3·4 to 8·9)
Canada 21 180 
(18 219 to 24 243)
–1·4 
(–9·2 to 6·9)
317 027 
(280 886 to 352 468)
–5·9 
(–10·1 to –1·0)
214 389 
(184 640 to 244 637)
–4·6 
(–11·5 to 3·3)
Greenland 5 
(4 to 7)
–2·0 
(–16·1 to 13·4)
151 
(125 to 178)
–4·0 
(–7·1 to –0·5)
99 
(76 to 127)
–4·1 
(–16·1 to 9·1)
USA 238 895 
(214 341 to 264 774)
11·6 
(4·4 to 19·1)
4 029 450 
(3 696 312 to 4 387 981)
–0·5 
(–6·4 to 6·4)
2 473 390 
(2 204 607 to 
2 768 700)
3·8 
(–2·5 to 10·8)
Australasia 17 668 
(15 110 to 20 461)
–6·2 
(–13·0 to 1·7)
251 413 
(217 349 to 287 182)
–9·1 
(–15·4 to –4·0)
176 255 
(151 230 to 206 647)
–8·2 
(–14·5 to –1·2)
Australia 14 977 
(12 862 to 17 417)
–6·0 
(–14·2 to 3·7)
211 208 
(183 061 to 240 574)
–9·2 
(–16·5 to –3·1)
148 229 
(127 148 to 173 753)
–8·3 
(–15·6 to 0·2)
New Zealand 2691 
(2226 to 3250)
–7·0 
(–15·6 to 1·9)
40 206 
(33 855 to 47 870)
–8·4 
(–15·1 to –3·5)
28 026 
(23 231 to 34 113)
–7·6 
(–14·9 to 0·1)
High-income Asia-Pacific 262 278 
(225 685 to 303 507)
9·2 
(4·6 to 14·3)
4 216 158 
(3 589 877 to 
4 949 994)
15·6 
(13·7 to 17·4)
2 678 775 
(2 274 031 to 
3 178 849)
9·3 
(5·0 to 14·2)
Brunei 61 
(50 to 75)
2·7 
(–7·4 to 13·3)
1311 
(1119 to 1530)
–4·1 
(–7·1 to –0·8)
876 
(723 to 1055)
0·8 
(–8·7 to 10·0)
Japan 224 138 
(194 703 to 258 848)
10·2 
(6·8 to 13·6)
3 530 611 
(2 999 793 to 4 177 416)
17·8 
(15·7 to 19·8)
2 226 531 
(1 894 705 to 
2 641 329)
10·5 
(7·5 to 13·2)
Singapore 2265 
(1793 to 2805)
3·2 
(–17·6 to 28·4)
37 905 
(31 673 to 44 582)
11·5 
(0·5 to 26·8)
24 746 
(19 932 to 30 529)
6·3 
(–12·5 to 28·8)
South Korea 35 814 
(26 742 to 46 764)
–2·6 
(–25·2 to 24·9)
646 331 
(558 444 to 744 282)
–4·2 
(–9·4 to 0·5)
426 622 
(329 392 to 542 917)
–4·5 
(–23·7 to 18·3)
Western Europe 452 515 
(389 889 to 523 953)
–7·4 
(–10·8 to –3·7)
6 586 827 
(5 634 206 to 
7 629 868)
–8·1 
(–10·9 to –5·3)
4 499 078 
(3 822 323 to 
5 279 978)
–8·6 
(–12·0 to –5·3)
Andorra 99 
(78 to 123)
–3·2 
(–21·4 to 23·7)
1253 
(1060 to 1492)
–4·9 
(–8·4 to –1·6)
901 
(723 to 1116)
–4·4 
(–20·4 to 17·7)
Austria 8270 
(6966 to 9742)
–5·7 
(–11·8 to 0·7)
126 914 
(106 564 to 151 088)
–3·9 
(–7·3 to –0·1)
84 853 
(71 330 to 100 942)
–5·8 
(–11·1 to –0·3)
Belgium 12 590 
(10 464 to 15 119)
–7·3 
(–17·1 to 1·9)
181 350 
(153 218 to 215 482)
–9·2 
(–15·4 to –3·8)
125 538 
(104 406 to 150 465)
–8·8 
(–17·2 to –0·8)
Cyprus 670 
(564 to 795)
–8·1 
(–14·9 to –0·6)
9644 
(8181 to 11 464)
–1·7 
(–4·6 to 1·5)
6844 
(5754 to 8245)
–9·0 
(–14·6 to –2·3)
Denmark 3984 
(3264 to 4768)
–12·3 
(–24·3 to –0·7)
55 336 
(47 063 to 64 457)
–20·1 
(–29·4 to –13·7)
39 831 
(33 115 to 47 717)
–17·1 
(–28·1 to –6·6)
(Table continues on next page)
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Deaths (95% UI) Prevalence (95% UI) DALYs (95% UI)
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Finland 6686 
(5486 to 8082)
–2·3 
(–11·1 to 6·7)
83 950 
(70 832 to 99 790)
–7·4 
(–13·6 to –2·7)
66 130 
(54 299 to 81 192)
–5·0 
(–13·0 to 2·6)
France 65 775 
(55 179 to 78 174)
–0·6 
(–8·5 to 8·0)
877 760 
(739 227 to 1 050 674)
1·1 
(–5·4 to 10·2)
611 185 
(513 043 to 731 084)
–1·7 
(–9·0 to 6·4)
Germany 77 634 
(62 763 to 93 488)
–20·8 
(–35·2 to –8·9)
1 201 668 
(996 430 to 1 425 812)
–17·7 
(–28·4 to –10·3)
823 713 
(673 054 to 1 007 932)
–18·4 
(–29·4 to –8·5)
Greece 12 568 
(10 418 to 14 981)
–5·4 
(–12·3 to 2·1)
192 563 
(161 441 to 229 260)
–3·7 
(–7·1 to –0·3)
128 762 
(106 552 to 154 548)
–5·4 
(–11·4 to 1·1)
Iceland 241 
(199 to 287)
–0·1 
(–8·8 to 9·0)
3373 
(2842 to 4000)
–6·5 
(–9·6 to –3·7)
2431 
(2019 to 2932)
–2·9 
(–10·1 to 4·7)
Ireland 2791 
(2280 to 3337)
–5·0 
(–15·1 to 6·9)
43 235 
(36 676 to 51 258)
–4·9 
(–8·2 to –1·0)
29 432 
(24 290 to 35 763)
–6·0 
(–14·3 to 4·2)
Israel 4730 
(3860 to 5906)
–5·2 
(–19·2 to 10·8)
69 596 
(58 898 to 82 970)
–3·9 
(–7·2 to –0·8)
46 920 
(38 028 to 57 408)
–6·1 
(–18·5 to 7·2)
Italy 90 981 
(76 553 to 105 860)
–1·8 
(–12·1 to 9·1)
1 370 308 
(1 152 154 to 1 583 588)
–2·9 
(–11·3 to 4·7)
898 329 
(756 615 to 1 050 918)
–4·4 
(–13·4 to 4·6)
Luxembourg 353 
(290 to 421)
–6·6 
(–16·8 to 3·6)
5022 
(4319 to 5912)
–10·9 
(–17·7 to –5·4)
3566 
(2985 to 4264)
–9·7 
(–18·6 to –0·6)
Malta 312 
(250 to 384)
–4·0 
(–18·5 to 10·2)
5145 
(4332 to 6119)
–4·5 
(–7·7 to –1·2)
3465 
(2780 to 4309)
–5·0 
(–16·8 to 7·1)
Netherlands 13 713 
(11 747 to 15 989)
–14·2 
(–22·3 to –5·3)
192 425 
(169 675 to 221 880)
–16·8 
(–24·8 to –8·7)
136 421 
(116 347 to 160 138)
–15·9 
(–23·7 to –7·2)
Norway 4777 
(3969 to 5736)
–7·2 
(–16·2 to 3·8)
67 207 
(57 096 to 79 609)
–9·7 
(–16·1 to –4·0)
46 646 
(39 007 to 56 232)
–9·3 
(–17·6 to 0·4)
Portugal 10 824 
(9034 to 12 860)
–4·2 
(–11·1 to 2·8)
166 660 
(139 562 to 201 560)
–4·3 
(–8·0 to –0·9)
113 147 
(94 134 to 137 267)
–4·9 
(–11·0 to 1·4)
Spain 57 098 
(49 114 to 65 392)
–9·6 
(–17·3 to –1·8)
830 915 
(712 248 to 952 265)
–12·7 
(–17·0 to –8·7)
561 948 
(480 867 to 646 417)
–12·4 
(–19·1 to –6·0)
Sweden 9658 
(7866 to 11 723)
–0·4 
(–10·5 to 11·4)
142 735 
(121 220 to 169 371)
–4·0 
(–9·0 to 0·4)
93 782 
(77 008 to 113 348)
–2·7 
(–11·0 to 6·4)
Switzerland 8234 
(6373 to 10 456)
–1·7 
(–19·8 to 19·9)
115 476 
(97 869 to 138 074)
–6·1 
(–10·6 to –2·2)
80 676 
(63 754 to 100 552)
–5·0 
(–20·1 to 12·8)
UK 60 525 
(51 581 to 70 828)
–6·8 
(–8·8 to –4·3)
838 693 
(708 801 to 995 493)
–10·3 
(–11·7 to –9·1)
593 711 
(499 978 to 706 382)
–8·4 
(–10·2 to –6·3)
Southern Latin America 23 831 
(19 455 to 28 671)
–3·5 
(–10·7 to 5·0)
375 984 
(315 602 to 448 261)
–4·4 
(–7·0 to –2·0)
257 496 
(211 125 to 311 373)
–4·6 
(–10·7 to 2·5)
Argentina 15 412 
(12 605 to 18 722)
–2·7 
(–10·5 to 5·7)
243 618 
(205 012 to 290 358)
–4·0 
(–7·1 to –0·7)
167 002 
(136 040 to 202 061)
–3·6 
(–10·2 to 2·9)
Chile 6508 
(4983 to 8392)
–5·3 
(–23·4 to 15·6)
104 523 
(87 150 to 124 669)
–5·9 
(–12·4 to 0·0)
70 944 
(55 336 to 90 933)
–7·2 
(–22·4 to 10·9)
Uruguay 1911 
(1569 to 2289)
–5·2 
(–12·4 to 2·5)
27 817 
(23 177 to 33 439)
–4·6 
(–7·4 to –1·7)
19 546 
(16 151 to 23 493)
–6·1 
(–11·7 to 0·4)
Eastern Europe 84 368 
(65 165 to 109 655)
–0·3 
(–16·0 to 17·6)
1 554 081 
(1 291 061 to 
1 855 425)
–1·2 
(–3·7 to 1·3)
1 037 741 
(811 281 to 
1 331 933)
–0·5 
(–13·7 to 15·0)
Belarus 4060 
(3179 to 5018)
1·3 
(–12·4 to 16·8)
72 664 
(60 673 to 87 181)
–1·2 
(–5·2 to 2·9)
48 733 
(38 985 to 60 585)
0·4 
(–11·3 to 13·3)
Estonia 805 
(638 to 995)
–0·2 
(–11·9 to 8·9)
13 540 
(11 248 to 16 325)
–1·6 
(–6·1 to 2·5)
9159 
(7408 to 11 307)
–1·1 
(–10·9 to 7·3)
Latvia 1202 
(976 to 1472)
0·0 
(–10·0 to 11·7)
20 677 
(17 216 to 24 940)
–0·5 
(–3·9 to 3·1)
13 994 
(11 352 to 17 189)
–0·4 
(–9·4 to 9·4)
Lithuania 1769 
(1440 to 2170)
0·6 
(–6·4 to 8·5)
30 147 
(25 142 to 36 420)
–0·8 
(–4·3 to 3·2)
20 304 
(16 653 to 24 872)
0·1 
(–6·0 to 6·9)
Moldova 1100 
(905 to 1385)
–3·5 
(–13·7 to 7·5)
20 777 
(17 415 to 24 766)
–1·6 
(–4·5 to 1·9)
13 823 
(11 327 to 17 136)
–2·1 
(–10·7 to 7·2)
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Russia 55 562 
(39 767 to 75 905)
0·0 
(–23·1 to 27·2)
1 025 660 
(849 865 to 1 229 568)
–1·0 
(–4·8 to 3·1)
685 106 
(508 315 to 920 093)
–0·3 
(–20·1 to 23·7)
Ukraine 19 870 
(15 171 to 26 624)
–1·3 
(–18·1 to 18·8)
370 615 
(306 917 to 442 613)
–1·6 
(–4·8 to 2·2)
246 622 
(191 357 to 320 476)
–1·3 
(–16·0 to 16·1)
Central Europe 59 119 
(49 158 to 71 242)
–2·9 
(–6·8 to 1·1)
1 033 615 
(861 756 to 1 235 186)
–3·5 
(–6·8 to –1·4)
696 428 
(576 669 to 845 438)
–3·9 
(–7·9 to –0·2)
Albania 958 
(772 to 1165)
–3·4 
(–15·0 to 8·5)
18 048 
(15 048 to 21 732)
–1·6 
(–5·3 to 2·9)
11 979 
(9651 to 14 810)
–3·0 
(–12·4 to 7·3)
Bosnia and Herzegovina 1751 
(1388 to 2195)
–2·2 
(–16·5 to 13·8)
31 804 
(26 614 to 37 994)
–0·5 
(–4·0 to 3·5)
21 217 
(17 002 to 26 502)
–2·1 
(–14·1 to 11·1)
Bulgaria 4140 
(3320 to 5247)
–1·4 
(–12·4 to 10·5)
76 346 
(63 003 to 92 366)
–0·6 
(–4·8 to 2·8)
51 189 
(41 554 to 64 039)
–1·7 
(–11·9 to 8·8)
Croatia 2690 
(2172 to 3335)
–0·3 
(–12·7 to 12·2)
45 148 
(37 772 to 53 815)
–1·3 
(–4·9 to 2·3)
30 976 
(25 056 to 38 427)
–0·9 
(–11·1 to 9·3)
Czech Republic 5474 
(4533 to 6592)
–2·6 
(–8·8 to 4·1)
96 200 
(80 221 to 115 100)
–1·4 
(–4·9 to 2·6)
64 628 
(53 720 to 78 313)
–3·3 
(–8·7 to 2·4)
Hungary 5523 
(4505 to 6773)
–1·0 
(–10·4 to 8·8)
94 633 
(78 970 to 113 490)
–1·6 
(–5·7 to 2·0)
64 456 
(52 914 to 79 536)
–1·4 
(–9·8 to 7·4)
Macedonia 654 
(543 to 798)
1·2 
(–5·8 to 8·6)
12 787 
(10 606 to 15 262)
0·3 
(–3·4 to 4·0)
8600 
(7095 to 10 502)
0·7 
(–5·6 to 6·8)
Montenegro 248 
(200 to 302)
1·4 
(–10·4 to 12·7)
4553 
(3772 to 5472)
0·4 
(–3·0 to 3·8)
3040 
(2460 to 3698)
1·3 
(–8·7 to 11·4)
Poland 19 488 
(15 936 to 23 766)
–6·6 
(–15·8 to 3·2)
333 656 
(277 898 to 399 034)
–8·8 
(–18·1 to –3·0)
224 088 
(184 403 to 272 346)
–8·7 
(–17·5 to 0·2)
Romania 10 269 
(8497 to 12 553)
–1·3 
(–10·1 to 7·4)
182 066 
(151 548 to 217 820)
–0·9 
(–4·6 to 3·0)
122 264 
(99 571 to 150 538)
–1·5 
(–9·4 to 6·2)
Serbia 4305 
(3582 to 5283)
1·8 
(–6·1 to 11·1)
76 985 
(64 237 to 91 993)
–0·4 
(–3·8 to 3·5)
52 068 
(43 092 to 63 732)
0·8 
(–5·9 to 8·9)
 Slovakia 2259 
(1826 to 2804)
–0·6 
(–10·3 to 11·1)
39 642 
(33 110 to 47 216)
–1·3 
(–4·9 to 2·8)
27 138 
(22 050 to 33 781)
–1·4 
(–10·1 to 8·4)
Slovenia 1359 
(1095 to 1661)
–4·6 
(–16·0 to 7·7)
21 745 
(18 129 to 26 165)
–2·4 
(–5·5 to 1·3)
14 785 
(11 857 to 18 020)
–5·1 
(–14·7 to 5·1)
Central Asia 12 669 
(10 564 to 15 413)
–1·0 
(–5·5 to 3·9)
247 867 
(207 340 to 294 247)
–0·9 
(–2·6 to 0·9)
162 755 
(135 702 to 197 877)
–1·3 
(–5·4 to 3·0)
Armenia 1060 
(876 to 1307)
3·6 
(–6·8 to 14·7)
18 476 
(15 412 to 22 206)
–0·5 
(–3·9 to 3·0)
12 426 
(10 313 to 15 383)
2·0 
(–6·8 to 11·3)
Azerbaijan 1506 
(1197 to 1883)
1·9 
(–10·2 to 17·7)
30 747 
(25 808 to 36 580)
0·4 
(–3·1 to 3·9)
20 191 
(16 307 to 25 036)
1·0 
(–9·7 to 14·8)
Georgia 1806 
(1461 to 2234)
2·2 
(–13·4 to 16·3)
30 310 
(25 251 to 36 053)
0·2 
(–3·7 to 4·3)
20 639 
(16 866 to 25 643)
1·7 
(–11·3 to 14·1)
Kazakhstan 2603 
(2097 to 3358)
–4·2 
(–17·6 to 10·7)
56 927 
(47 459 to 68 027)
–0·8 
(–4·7 to 2·7)
35 883 
(28 877 to 45 860)
–3·9 
(–15·5 to 8·7)
Kyrgyzstan 677 
(557 to 816)
–0·2 
(–7·9 to 8·1)
13 141 
(11 032 to 15 644)
–0·2 
(–4·2 to 3·6)
8702 
(7189 to 10 576)
0·2 
(–6·7 to 7·3)
Mongolia 265 
(213 to 327)
–1·8 
(–13·6 to 10·9)
5635 
(4703 to 6648)
–0·2 
(–3·6 to 3·2)
3735 
(2989 to 4546)
–3·3 
(–13·4 to 8·0)
Tajikistan 655 
(535 to 806)
–2·2 
(–12·3 to 11·0)
12 872 
(10 841 to 15 131)
–4·2 
(–7·3 to –0·7)
8596 
(7103 to 10 510)
–2·8 
(–11·8 to 9·1)
Turkmenistan 506 
(424 to 608)
–4·6 
(–10·8 to 2·3)
10 455 
(8785 to 12 366)
–2·3 
(–5·6 to 1·1)
6766 
(5636 to 8176)
–4·3 
(–9·7 to 1·4)
Uzbekistan 3591 
(2942 to 4390)
–1·3 
(–9·7 to 7·9)
69 303 
(57 761 to 81 697)
–0·9 
(–4·5 to 2·5)
45 817 
(37 701 to 56 067)
–1·3 
(–8·5 to 6·4)
(Table continues on next page)
Articles
94 www.thelancet.com/neurology   Vol 18   January 2019
Deaths (95% UI) Prevalence (95% UI) DALYs (95% UI)
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Central Latin America 67 443 
(56 996 to 80 037)
–7·2 
(–10·0 to –4·2)
1 268 251 
(1 073 553 to 
1 503 468)
–5·2 
(–6·5 to –4·2)
819 513 
(685 355 to 989 762)
–6·9 
(–9·3 to –4·4)
Colombia 12 384 
(10 275 to 14 879)
–7·3 
(–14·6 to 0·9)
248 583 
(210 857 to 295 501)
–4·9 
(–7·8 to –1·8)
158 120 
(130 223 to 189 645)
–6·8 
(–13·1 to 0·3)
Costa Rica 1687 
(1417 to 2012)
–6·0 
(–13·7 to 1·5)
31 865 
(26 781 to 37 969)
–4·2 
(–7·3 to –0·7)
20 526 
(17 088 to 24 631)
–5·8 
(–12·3 to 0·4)
El Salvador 2124 
(1761 to 2563)
–6·3 
(–15·6 to 3·3)
37 416 
(31 301 to 44 669)
–3·7 
(–7·4 to –0·5)
25 185 
(20 658 to 30 567)
–7·0 
(–14·8 to 1·0)
Guatemala 3052 
(2304 to 3929)
–2·6 
(–20·9 to 18·0)
57 458 
(48 152 to 67 876)
–2·6 
(–5·8 to 0·7)
38 267 
(29 854 to 48 962)
–3·8 
(–19·7 to 14·2)
Honduras 1847 
(1418 to 2291)
–2·0 
(–19·8 to 17·0)
30 015 
(25 259 to 35 678)
–4·3 
(–7·5 to –1·3)
22 506 
(17 410 to 28 506)
–3·6 
(–19·0 to 14·0)
Mexico 37 128 
(31 423 to 44 041)
–6·2 
(–9·4 to –3·1)
679 581 
(571 934 to 806 887)
–3·9 
(–5·0 to –3·0)
437 563 
(367 299 to 525 198)
–5·5 
(–7·9 to –3·2)
Nicaragua 1390 
(1136 to 1696)
–5·0 
(–17·2 to 8·3)
25 410 
(21 451 to 30 239)
–3·9 
(–7·4 to –0·5)
16 428 
(13 353 to 20 057)
–4·8 
(–15·2 to 6·8)
Panama 1227 
(1014 to 1507)
–8·2 
(–18·8 to 3·7)
22 348 
(18 867 to 26 700)
–6·6 
(–9·9 to –3·2)
14 478 
(11 989 to 17 779)
–8·3 
(–17·6 to 2·0)
Venezuela 6605 
(5342 to 8050)
–15·1 
(–25·9 to –1·7)
135 574 
(115 292 to 158 925)
–13·4 
(–20·5 to –8·6)
86 441 
(69 422 to 106 289)
–15·4 
(–24·7 to –3·2)
Andean Latin America 11 513 
(9504 to 14 155)
–3·2 
(–12·3 to 6·9)
201 807 
(171 097 to 237 657)
–6·0 
(–8·5 to –3·6)
137 206 
(113 336 to 168 798)
–4·5 
(–12·0 to 3·7)
Bolivia 2285 
(1759 to 2899)
2·9 
(–11·7 to 21·3)
38 118 
(31 800 to 45 400)
–3·5 
(–6·2 to –0·5)
27 439 
(21 628 to 34 385)
0·5 
(–12·8 to 16·8)
Ecuador 3023 
(2500 to 3608)
–6·3 
(–13·2 to 1·1)
55 865 
(47 213 to 65 937)
–5·1 
(–8·3 to –1·8)
36 711 
(30 333 to 44 613)
–7·0 
(–13·0 to –0·7)
Peru 6205 
(4847 to 7733)
–4·0 
(–19·2 to 12·8)
107 824 
(91 186 to 126 723)
–7·5 
(–11·6 to –3·4)
73 056 
(58 539 to 90 994)
–5·1 
(–17·5 to 9·2)
Caribbean 13 624 
(11 487 to 16 276)
–3·5 
(–8·4 to 1·6)
244 819 
(206 229 to 289 536)
–4·9 
(–6·5 to –3·2)
161 853 
(135 793 to 197 434)
–4·4 
(–8·6 to –0·1)
Antigua and Barbuda 21 
(17 to 25)
0·6 
(–10·8 to 13·4)
372 
(312 to 439)
–1·6 
(–5·1 to 1·8)
252 
(206 to 307)
–0·5 
(–10·1 to 10·8)
The Bahamas 88 
(71 to 108)
4·1 
(–6·6 to 15·8)
1688 
(1413 to 2012)
0·5 
(–2·5 to 4·4)
1162 
(944 to 1420)
2·1 
(–6·8 to 12·0)
Barbados 136 
(111 to 164)
5·7 
(–4·2 to 16·1)
2224 
(1869 to 2641)
–2·0 
(–5·3 to 1·7)
1557 
(1284 to 1890)
2·7 
(–5·4 to 11·5)
Belize 37 
(30 to 46)
4·6 
(–7·5 to 17·1)
707 
(599 to 836)
–3·9 
(–7·1 to –0·7)
505 
(419 to 609)
2·7 
(–8·8 to 13·8)
Bermuda 21 
(17 to 26)
–1·0 
(–14·8 to 14·1)
356 
(301 to 423)
–4·0 
(–7·3 to –0·8)
249 
(201 to 309)
–3·2 
(–14·3 to 9·0)
Cuba 6149 
(5118 to 7370)
–3·2 
(–11·7 to 6·0)
103 227 
(86 496 to 122 320)
–4·8 
(–7·9 to –1·4)
70 115 
(58 080 to 84 845)
–4·3 
(–11·3 to 3·1)
Dominica 21 
(17 to 26)
0·7 
(–9·7 to 13·5)
357 
(299 to 427)
–3·5 
(–6·9 to –0·4)
246 
(201 to 301)
–1·8 
(–10·6 to 9·2)
Dominican Republic 2233 
(1796 to 2743)
–7·6 
(–20·4 to 5·4)
39 760 
(33 575 to 47 321)
–6·2 
(–9·4 to –3·1)
26 694 
(21 595 to 32 836)
–8·0 
(–19·0 to 3·2)
Grenada 28 
(23 to 34)
5·1 
(–7·0 to 16·9)
449 
(375 to 534)
–2·7 
(–5·8 to 0·5)
319 
(261 to 390)
2·8 
(–7·4 to 13·0)
Guyana 80 
(66 to 96)
2·5 
(–7·0 to 12·5)
1850 
(1570 to 2186)
–1·6 
(–5·2 to 1·5)
1221 
(1002 to 1480)
0·1 
(–7·8 to 8·9)
Haiti 1192 
(931 to 1499)
1·7 
(–11·4 to 15·8)
24 561 
(20 588 to 29 210)
–6·3 
(–9·5 to –2·6)
17 213 
(13 710 to 21 591)
–0·7 
(–12·0 to 11·3)
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Jamaica 951 
(773 to 1166)
1·5 
(–12·2 to 16·2)
15 075 
(12 743 to 17 797)
–4·3 
(–7·6 to –1·3)
10 501 
(8566 to 12 957)
0·1 
(–11·6 to 12·3)
Puerto Rico 2081 
(1686 to 2535)
1·3 
(–7·3 to 10·8)
31 203 
(26 216 to 37 065)
–2·9 
(–6·1 to 0·3)
22 554 
(18 612 to 27 815)
–0·8 
(–8·3 to 7·2)
Saint Lucia 57 
(47 to 69)
1·2 
(–6·3 to 9·0)
975 
(811 to 1156)
–2·1 
(–5·5 to 1·2)
672 
(553 to 817)
0·1 
(–6·2 to 6·7)
Saint Vincent and the Grenadines 24 
(20 to 29)
–5·8 
(–14·2 to 3·1)
454 
(383 to 539)
–4·6 
(–7·5 to –1·6)
307 
(255 to 373)
–5·6 
(–12·8 to 2·2)
Suriname 118 
(98 to 143)
7·3 
(–1·3 to 16·8)
2097 
(1764 to 2484)
–1·6 
(–4·3 to 1·5)
1487 
(1225 to 1797)
3·6 
(–3·9 to 11·3)
Trinidad and Tobago 340 
(283 to 410)
–3·3 
(–10·7 to 4·9)
6739 
(5667 to 7967)
–2·9 
(–6·1 to 0·4)
4441 
(3665 to 5432)
–4·2 
(–10·4 to 2·8)
Virgin Islands 48 
(39 to 58)
–5·6 
(–13·7 to 5·0)
881 
(737 to 1051)
–4·0 
(–7·2 to –0·5)
613 
(501 to 751)
–6·2 
(–13·8 to 2·9)
Tropical Latin America 82 383 
(70 588 to 97 167)
0·1 
(–3·7 to 4·0)
1 725 736 
(1 470 749 to 
2 025 314)
5·0 
(2·4 to 7·9)
1 104 940 
(931 687 to 
1 314 278)
3·1 
(–0·3 to 6·7)
Brazil 80 600 
(69 174 to 94 940)
0·1 
(–3·7 to 4·0)
1 691 024 
(1 440 967 to 1 983 529)
5·2 
(2·5 to 8·2)
1 081 903 
(911 837 to 1 287 687)
3·2 
(–0·2 to 6·8)
Paraguay 1783 
(1467 to 2186)
–2·0 
(–12·6 to 8·8)
34 712 
(29 060 to 41 134)
–6·1 
(–8·9 to –3·0)
23 037 
(18 916 to 28 040)
–3·3 
(–12·3 to 5·9)
East Asia 495 128 
(423 608 to 582 787)
–0·5 
(–9·5 to 4·3)
10 767 181 
(9 212 998 to 
12 591 276)
5·4 
(4·2 to 6·7)
6 866 579 
(5 812 325 to 
8 086 374)
0·2 
(–6·6 to 4·0)
China 476 898 
(407 695 to 560 628)
–0·1 
(–9·5 to 4·9)
10 427 487 
(8 917 543 to 
12 196 329)
5·6 
(4·4 to 6·9)
6 637 268 
(5 606 035 to 
7 806 164)
0·5 
(–6·5 to 4·4)
North Korea 6098 
(5062 to 7511)
3·4 
(–8·5 to 19·6)
136 430 
(114 541 to 161 576)
–3·8 
(–7·0 to –0·4)
90 179 
(74 251 to 108 648)
2·5 
(–7·5 to 15·7)
Taiwan (province of China) 12 132 
(9878 to 14 776)
–14·6 
(–26·3 to 0·6)
203 264 
(171 769 to 238 879)
11·1 
(3·6 to 23·8)
139 132 
(114 655 to 168 804)
–9·7 
(–20·8 to 4·3)
Southeast Asia 168 498 
(143 918 to 200 845)
6·5 
(0·3 to 14·6)
3 337 721 
(2 835 683 to 
3 942 605)
–1·5 
(–2·6 to –0·4)
2 295 779 
(1 935 096 to 
2 717 204)
3·8 
(–1·0 to 9·5)
Cambodia 2439 
(2073 to 2955)
17·8 
(4·0 to 44·7)
50 393 
(42 605 to 59 560)
–3·9 
(–7·3 to –0·6)
37 733 
(31 661 to 45 301)
11·4 
(0·8 to 30·8)
Indonesia 45 591 
(38 307 to 54 896)
32·6 
(17·1 to 54·6)
1 111 081 
(942 834 to 1 320 195)
–0·1 
(–1·3 to 1·1)
703 600 
(581 417 to 843 705)
20·6 
(10·9 to 33·8)
Laos 919 
(760 to 1126)
15·5 
(2·7 to 33·4)
20 678 
(17 491 to 24 443)
–1·5 
(–5·1 to 2·1)
13 805 
(11 264 to 16 642)
10·2 
(0·6 to 22·7)
Malaysia 6579 
(5517 to 7893)
–7·6 
(–14·1 to 0·7)
159 491 
(135 859 to 189 529)
–0·9 
(–4·8 to 3·3)
100 999 
(84 056 to 121 357)
–6·8 
(–12·5 to 0·1)
Maldives 70 
(55 to 87)
1·2 
(–14·0 to 21·6)
1464 
(1236 to 1731)
0·5 
(–2·5 to 4·0)
948 
(761 to 1166)
1·2 
(–12·1 to 19·4)
Mauritius 462 
(382 to 559)
–6·0 
(–15·9 to 5·6)
9941 
(8400 to 11 689)
–3·1 
(–6·7 to 0·2)
6282 
(5196 to 7502)
–6·5 
(–14·9 to 3·3)
Myanmar 17 857 
(15 099 to 21 127)
8·8 
(–2·3 to 22·6)
232 112 
(198 607 to 272 903)
–3·1 
(–6·4 to 0·2)
240 489 
(199 922 to 286 798)
4·5 
(–5·0 to 15·8)
Philippines 14 942 
(12 213 to 18 279)
1·3 
(–10·3 to 13·4)
359 689 
(304 824 to 426 756)
–0·8 
(–3·8 to 2·3)
230 296 
(187 155 to 280 412)
0·6 
(–9·5 to 11·0)
Sri Lanka 6680 
(5277 to 8346)
–10·4 
(–26·6 to 7·1)
127 331 
(107 863 to 149 887)
–0·1 
(–3·5 to 3·9)
86 779 
(69 960 to 107 916)
–7·4 
(–22·0 to 8·2)
Seychelles 36 
(30 to 43)
–2·4 
(–10·7 to 6·4)
653 
(551 to 769)
–1·1 
(–3·9 to 2·0)
439 
(364 to 526)
–3·0 
(–10·2 to 4·9)
Thailand 30 293 
(24 884 to 37 126)
–5·2 
(–15·9 to 7·6)
597 698 
(505 189 to 703 496)
–1·5 
(–5·0 to 2·2)
395 408 
(325 461 to 482 250)
–5·2 
(–13·9 to 4·9)
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Timor-Leste 172 
(134 to 219)
16·0 
(–4·9 to 51·2)
3976 
(3338 to 4745)
–1·2 
(–4·5 to 2·1)
2761 
(2165 to 3458)
11·5 
(–6·4 to 38·4)
Vietnam 42 459 
(35 595 to 50 802)
1·8 
(–10·9 to 17·8)
655 099 
(558 892 to 775 483)
–2·6 
(–6·0 to 0·7)
475 067 
(398 602 to 568 773)
–0·4 
(–11·3 to 13·1)
Oceania 968 
(794 to 1187)
–7·3 
(–14·5 to 0·8)
28 064 
(23 704 to 33 276)
–1·6 
(–3·8 to 0·2)
16 322 
(13 394 to 19 833)
–5·9 
(–12·6 to 1·3)
American Samoa 8 
(6 to 9)
–5·0 
(–17·5 to 8·9)
173 
(147 to 204)
1·0 
(–2·7 to 4·7)
114 
(92 to 138)
–4·5 
(–15·4 to 8·2)
Federated States of Micronesia 18 
(14 to 22)
–2·6 
(–15·4 to 13·3)
311 
(263 to 364)
–1·0 
(–4·7 to 2·8)
251 
(197 to 313)
–3·3 
(–16·1 to 12·8)
Fiji 127 
(99 to 163)
–7·2 
(–24·3 to 13·5)
3182 
(2676 to 3767)
–0·7 
(–4·0 to 3·1)
2049 
(1629 to 2575)
–6·3 
(–22·3 to 12·2)
Guam 54 
(44 to 66)
–6·1 
(–15·3 to 4·4)
1061 
(890 to 1259)
–1·8 
(–5·1 to 1·8)
721 
(588 to 871)
–5·5 
(–13·9 to 3·8)
Kiribati 18 
(15 to 23)
13·8 
(–0·5 to 31·0)
298 
(253 to 352)
–1·2 
(–4·4 to 1·7)
269 
(220 to 333)
9·1 
(–3·7 to 24·1)
Marshall Islands 5 
(4 to 7)
–15·9 
(–25·5 to –5·2)
159 
(134 to 189)
–1·7 
(–5·0 to 1·8)
92 
(74 to 115)
–13·8 
(–22·4 to –4·0)
Northern Mariana Islands 6 
(5 to 7)
–4·3 
(–19·5 to 15·7)
129 
(111 to 149)
–1·9 
(–5·2 to 1·9)
85 
(70 to 105)
–5·1 
(–18·5 to 12·0)
Papua New Guinea 555 
(439 to 701)
1·6 
(–11·1 to 16·3)
15 398 
(13 008 to 18 206)
–2·2 
(–5·7 to 1·0)
9665 
(7658 to 11 921)
–0·7 
(–11·4 to 11·8)
Samoa 50 
(41 to 62)
–4·4 
(–15·9 to 9·5)
784 
(662 to 930)
–1·7 
(–5·0 to 1·3)
628 
(518 to 770)
–4·4 
(–15·3 to 8·6)
Solomon Islands 63 
(52 to 78)
3·4 
(–7·1 to 17·2)
1280 
(1081 to 1514)
–0·5 
(–3·8 to 2·5)
974 
(791 to 1195)
1·2 
(–8·7 to 14·6)
Tonga 31 
(26 to 38)
0·8 
(–12·9 to 16·9)
499 
(420 to 593)
0·0 
(–3·0 to 3·6)
374 
(308 to 460)
–0·1 
(–12·8 to 14·5)
Vanuatu 33 
(27 to 42)
2·5 
(–8·8 to 15·2)
708 
(594 to 843)
–1·1 
(–4·3 to 2·5)
530 
(429 to 669)
1·2 
(–9·6 to 13·4)
North Africa and Middle East 120 035 
(102 120 to 141 652)
–1·8 
(–7·6 to 4·8)
2 613 225 
(2 220 174 to 
3 075 460)
–1·0 
(–2·7 to 1·5)
1 669 040 
(1 404 463 to 
1 982 410)
–1·3 
(–6·2 to 4·0)
Afghanistan 2903 
(2360 to 3584)
7·1 
(–2·9 to 22·4)
65 639 
(54 920 to 77 796)
–1·5 
(–4·8 to 2·5)
48 654 
(39 657 to 59 945)
5·1 
(–4·1 to 17·0)
Algeria 11 868 
(9916 to 14 314)
–1·8 
(–10·9 to 8·0)
223 164 
(188 279 to 265 420)
–4·3 
(–7·4 to –1·0)
156 627 
(130 028 to 189 001)
–2·4 
(–10·1 to 6·7)
Bahrain 128 
(102 to 160)
–1·1 
(–16·2 to 15·6)
3091 
(2638 to 3618)
–2·1 
(–5·1 to 1·0)
1983 
(1576 to 2469)
–3·4 
(–16·5 to 11·2)
Egypt 14 929 
(12 172 to 18 150)
–1·5 
(–12·1 to 10·7)
355 367 
(306 335 to 409 862)
0·9 
(–3·0 to 5·4)
218 670 
(181 299 to 263 821)
–0·8 
(–10·3 to 9·7)
Iran 16 739 
(13 611 to 20 490)
3·7 
(–10·5 to 21·9)
368 528 
(311 492 to 437 404)
–1·2 
(–4·2 to 2·0)
235 690 
(189 845 to 288 441)
2·4 
(–10·5 to 18·8)
Iraq 4294 
(3433 to 5344)
–1·6 
(–16·4 to 13·4)
99 821 
(84 081 to 119 541)
–1·4 
(–4·8 to 2·2)
65 480 
(51 944 to 80 425)
–1·8 
(–15·9 to 12·4)
Jordan 1106 
(868 to 1416)
–3·8 
(–20·5 to 16·4)
25 413 
(21 281 to 30 183)
–0·8 
(–4·6 to 2·7)
16 197 
(12 628 to 20 464)
–3·5 
(–19·2 to 15·0)
Kuwait 265 
(197 to 344)
0·1 
(–20·8 to 25·1)
7097 
(6063 to 8425)
–2·5 
(–5·6 to 0·3)
4411 
(3363 to 5676)
–0·6 
(–18·5 to 21·5)
Lebanon 2071 
(1704 to 2531)
–12·5 
(–25·6 to 3·4)
45 656 
(37 962 to 54 771)
–3·0 
(–6·5 to 0·4)
27 451 
(22 314 to 33 342)
–12·6 
(–24·2 to 2·0)
Libya 1313 
(1096 to 1585)
–0·3 
(–10·9 to 10·5)
25 567 
(21 548 to 30 392)
–0·7 
(–3·8 to 2·6)
17 978 
(14 741 to 21 844)
–1·2 
(–10·8 to 8·9)
Morocco 9169 
(7460 to 11 204)
7·6 
(–6·5 to 38·1)
197 480 
(165 612 to 233 425)
–4·3 
(–7·6 to –0·8)
126 157 
(103 001 to 153 832)
4·5 
(–6·9 to 24·9)
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Oman 439 
(374 to 526)
–7·5 
(–17·3 to 3·8)
10 353 
(8822 to 12 263)
–4·9 
(–8·2 to –1·2)
6503 
(5393 to 7783)
–8·7 
(–17·2 to 0·9)
Palestine 497 
(414 to 605)
–2·7 
(–13·7 to 10·0)
11 635 
(9767 to 13 847)
–1·6 
(–5·3 to 2·3)
7619 
(6286 to 9256)
–2·3 
(–12·4 to 8·5)
Qatar 93 
(68 to 124)
–4·2 
(–26·7 to 22·0)
2706 
(2292 to 3174)
–2·7 
(–5·6 to 0·5)
1682 
(1255 to 2220)
–4·8 
(–23·7 to 19·8)
Saudi Arabia 4148 
(3515 to 4980)
3·8 
(–9·6 to 21·2)
91 232 
(77 702 to 107 276)
–0·2 
(–1·6 to 1·0)
58 495 
(48 953 to 69 907)
2·5 
(–8·8 to 16·4)
Sudan 4164 
(3425 to 5077)
8·1 
(–0·5 to 21·5)
99 360 
(83 462 to 118 168)
–2·8 
(–6·1 to 1·0)
63 559 
(52 164 to 77 052)
5·0 
(–2·2 to 14·5)
Syria 3132 
(2608 to 3727)
–0·6 
(–7·9 to 7·1)
68 793 
(58 115 to 81 155)
–2·5 
(–6·4 to 0·9)
44 016 
(36 492 to 53 053)
–1·2 
(–8·5 to 6·0)
Tunisia 4558 
(3681 to 5599)
–1·9 
(–16·9 to 12·3)
85 220 
(71 552 to 101 268)
–2·3 
(–5·4 to 0·8)
58 122 
(47 222 to 71 312)
–2·3 
(–15·6 to 10·2)
Turkey 35 355 
(28 754 to 43 599)
–7·2 
(–21·2 to 10·2)
754 169 
(639 274 to 887 565)
2·5 
(–2·4 to 9·9)
462 429 
(375 893 to 562 128)
–4·1 
(–16·5 to 11·2)
United Arab Emirates 318 
(261 to 389)
1·9 
(–14·1 to 21·2)
10 301 
(8769 to 12 096)
–4·3 
(–7·6 to –1·0)
6303 
(5108 to 7835)
0·2 
(–14·7 to 17·9)
Yemen 2547 
(2088 to 3117)
5·7 
(–5·6 to 20·8)
61 063 
(51 634 to 72 314)
–4·5 
(–7·7 to –0·7)
40 803 
(33 454 to 49 862)
2·9 
(–7·0 to 15·3)
South Asia 178 664 
(147 248 to 221 989)
16·6 
(5·5 to 28·6)
3 747 443 
(3 149 228 to 
4 457 380)
–4·6 
(–5·4 to –3·8)
2 494 935 
(2 063 839 to 
3 062 413)
9·1 
(1·8 to 16·6)
Bangladesh 16 463 
(13 583 to 20 470)
–25·9 
(–36·2 to –13·2)
401 328 
(337 842 to 477 034)
–0·6 
(–3·9 to 3·3)
229 138 
(187 502 to 282 360)
–22·6 
(–31·5 to –12·3)
Bhutan 100 
(80 to 123)
5·4 
(–10·8 to 26·8)
1712 
(1435 to 2023)
–2·8 
(–5·7 to 1·1)
1249 
(1020 to 1542)
1·5 
(–11·6 to 17·4)
India 142 927 
(117 019 to 177 846)
23·4 
(10·2 to 36·5)
2 933 814 
(2 466 582 to 3 493 076)
–5·5 
(–6·2 to –4·7)
1 996 152 
(1 642 642 to 
2 451 329)
13·5 
(5·5 to 21·9)
Nepal 3294 
(2678 to 4084)
27·0 
(3·6 to 57·2)
64 140 
(53 603 to 76 362)
–5·4 
(–8·6 to –2·0)
46 390 
(37 691 to 56 890)
14·8 
(–0·5 to 34·5)
Pakistan 15 880 
(12 814 to 19 871)
10·7 
(–6·2 to 38·4)
346 449 
(290 105 to 410 068)
–4·3 
(–7·4 to –1·3)
222 007 
(179 406 to 273 549)
5·8 
(–7·1 to 24·5)
Southern sub-Saharan Africa 10 893 
(9030 to 13 274)
9·9 
(0·9 to 18·8)
205 047 
(172 093 to 245 564)
–3·0 
(–4·2 to –1·7)
141 999 
(117 766 to 173 195)
6·4 
(–0·6 to 13·6)
Botswana 189 
(94 to 267)
2·2 
(–42·7 to 36·3)
3896 
(3270 to 4611)
–3·2 
(–7·0 to 0·7)
2759 
(1540 to 3845)
–0·5 
(–38·2 to 30·2)
eSwatini 86 
(55 to 123)
–7·5 
(–31·7 to 18·6)
1987 
(1659 to 2369)
–4·8 
(–8·0 to –1·3)
1316 
(884 to 1842)
–8·6 
(–29·7 to 15·0)
Lesotho 214 
(157 to 278)
0·7 
(–21·1 to 23·9)
4363 
(3630 to 5212)
–1·7 
(–5·2 to 2·4)
2965 
(2209 to 3875)
–0·9 
(–20·9 to 21·1)
Namibia 226 
(140 to 305)
2·2 
(–29·3 to 26·7)
4174 
(3493 to 4971)
–3·4 
(–6·6 to –0·2)
3186 
(2093 to 4263)
–0·7 
(–27·9 to 21·6)
South Africa 8545 
(7 118 to 10 394)
6·4 
(–2·4 to 15·2)
167 424 
(140 580 to 200 571)
–3·1 
(–4·4 to –1·8)
110 748 
(92 297 to 134 519)
3·4 
(–3·2 to 10·5)
Zimbabwe 1634 
(1262 to 2091)
40·1 
(17·4 to 97·7)
23 203 
(19 358 to 27 775)
–2·5 
(–5·9 to 1·1)
21 025 
(16 364 to 26 711)
31·2 
(10·6 to 76·1)
Western sub-Saharan Africa 19 288 
(15 849 to 23 579)
3·7 
(–3·7 to 11·3)
363 434 
(308 212 to 428 346)
–2·7 
(–4·8 to 0·3)
286 143 
(234 972 to 347 258)
1·8 
(–4·8 to 8·4)
Benin 622 
(506 to 769)
–4·5 
(–14·4 to 7·1)
11 021 
(9397 to 12 958)
–7·1 
(–11·8 to –2·7)
9361 
(7747 to 11 453)
–5·0 
(–14·2 to 5·7)
Burkina Faso 884 
(722 to 1104)
–3·6 
(–13·7 to 9·6)
15 600 
(13 128 to 18 543)
–3·9 
(–7·0 to –0·4)
13 124 
(10 715 to 16 097)
–5·2 
(–14·2 to 6·4)
Cameroon 1811 
(1405 to 2332)
–0·2 
(–14·4 to 15·0)
26 814 
(22 544 to 31 740)
–4·2 
(–7·4 to –1·0)
24 206 
(18 665 to 31 079)
–1·4 
(–15·4 to 13·4)
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Cape Verde 74 
(60 to 91)
4·4 
(–6·6 to 15·4)
1185 
(990 to 1417)
–3·8 
(–7·2 to 0·0)
866 
(705 to 1067)
1·7 
(–7·8 to 11·3)
Chad 723 
(588 to 896)
–4·2 
(–13·4 to 5·8)
12 784 
(10 755 to 15 100)
–4·0 
(–6·8 to –1·1)
10 307 
(8349 to 12 656)
–4·8 
(–13·7 to 4·9)
Côte d’Ivoire 1287 
(1033 to 1596)
3·1 
(–6·0 to 13·3)
22 894 
(19 142 to 27 192)
–3·1 
(–6·6 to 0·3)
19 796 
(15 952 to 24 347)
2·2 
(–6·4 to 11·7)
The Gambia 99 
(80 to 124)
4·4 
(–8·5 to 18·9)
1696 
(1432 to 2011)
–3·7 
(–6·9 to –0·1)
1428 
(1150 to 1763)
2·6 
(–9·9 to 15·4)
Ghana 1990 
(1599 to 2437)
12·0 
(–1·1 to 29·4)
32 390 
(27 243 to 38 466)
–3·0 
(–6·4 to 0·2)
27 517 
(22 421 to 33 454)
8·7 
(–3·1 to 23·4)
Guinea 765 
(615 to 957)
1·5 
(–11·3 to 13·9)
13 260 
(11 180 to 15 706)
–4·4 
(–7·2 to –1·2)
11 402 
(9270 to 14 231)
0·2 
(–11·9 to 11·3)
Guinea-Bissau 109 
(88 to 133)
–2·2 
(–11·8 to 10·5)
1993 
(1679 to 2360)
–4·4 
(–7·6 to –1·2)
1681 
(1352 to 2074)
–3·4 
(–12·9 to 8·6)
Liberia 249 
(202 to 307)
3·9 
(–5·7 to 16·1)
4642 
(3907 to 5539)
–3·5 
(–7·2 to 0·1)
3766 
(3060 to 4614)
2·3 
(–6·0 to 12·5)
Mali 924 
(733 to 1179)
4·6 
(–7·8 to 20·6)
15 724 
(13 238 to 18 678)
–3·7 
(–6·8 to 0·0)
12 949 
(10 224 to 16 284)
1·4 
(–10·5 to 16·5)
Mauritania 291 
(225 to 372)
3·0 
(–12·6 to 19·6)
4793 
(4035 to 5686)
–3·0 
(–6·0 to 0·5)
4113 
(3235 to 5295)
0·4 
(–14·1 to 15·0)
Niger 868 
(684 to 1103)
1·9 
(–9·1 to 16·5)
17 365 
(14 617 to 20 614)
–2·8 
(–6·0 to 0·5)
13 730 
(10 676 to 17 267)
0·9 
(–9·7 to 15·1)
Nigeria 6911 
(5333 to 8763)
6·0 
(–10·8 to 22·0)
152 733 
(129 008 to 179 828)
–0·9 
(–5·7 to 6·9)
107 197 
(83 511 to 134 751)
3·8 
(–11·7 to 18·3)
São Tomé and Príncipe 16 
(13 to 21)
3·2 
(–9·8 to 17·2)
259 
(217 to 311)
–3·5 
(–6·6 to 0·2)
199 
(159 to 247)
1·4 
(–10·0 to 13·2)
Senegal 1043 
(856 to 1284)
6·4 
(–2·4 to 16·0)
15 915 
(13 412 to 18 930)
–6·0 
(–9·2 to –2·7)
14 552 
(11 928 to 17 884)
3·5 
(–3·9 to 11·6)
Sierra Leone 246 
(196 to 305)
–0·3 
(–10·9 to 12·6)
5612 
(4710 to 6643)
–3·6 
(–6·5 to –0·3)
4222 
(3353 to 5182)
–0·7 
(–10·5 to 10·4)
Togo 376 
(303 to 463)
–1·7 
(–12·6 to 10·0)
6730 
(5653 to 8034)
–4·1 
(–7·6 to –0·9)
5723 
(4601 to 7009)
–2·3 
(–12·1 to 8·5)
Eastern sub-Saharan Africa 29 557 
(24 407 to 36 841)
6·5 
(0·1 to 14·7)
508 756 
(428 178 to 603 846)
–4·1 
(–5·4 to –2·8)
406 808 
(336 539 to 502 313)
3·5 
(–1·6 to 9·7)
Burundi 639 
(511 to 820)
4·2 
(–7·4 to 16·0)
12 408 
(10 409 to 14 752)
–4·4 
(–7·5 to –0·7)
9278 
(7425 to 11 594)
0·9 
(–9·7 to 12·0)
Comoros 58 
(47 to 72)
4·0 
(–8·9 to 17·4)
993 
(832 to 1172)
–4·1 
(–7·9 to –0·7)
807 
(657 to 990)
1·3 
(–10·6 to 13·3)
Djibouti 98 
(74 to 125)
6·4 
(–12·2 to 24·6)
1639 
(1378 to 1947)
–4·1 
(–6·9 to –1·2)
1325 
(1010 to 1679)
3·3 
(–13·8 to 19·9)
Eritrea 296 
(235 to 373)
9·4 
(–3·2 to 21·7)
5465 
(4580 to 6486)
–5·5 
(–9·0 to –1·9)
4487 
(3587 to 5602)
4·4 
(–5·8 to 15·7)
Ethiopia 8664 
(6923 to 10 914)
9·3 
(–3·9 to 26·1)
145 109 
(121 512 to 172 680)
–4·1 
(–7·7 to –0·5)
120 681 
(95 728 to 151 710)
6·0 
(–5·2 to 20·2)
Kenya 3205 
(2448 to 4091)
15·3 
(2·0 to 43·5)
61 120 
(51 624 to 72 287)
–2·1 
(–2·8 to –1·5)
42 739 
(33 585 to 53 535)
9·6 
(–0·4 to 26·2)
Madagascar 1486 
(1147 to 1876)
–1·4 
(–16·2 to 12·0)
31 885 
(26 736 to 37 901)
–3·1 
(–6·8 to 0·3)
21 798 
(17 049 to 27 350)
–1·2 
(–14·7 to 11·6)
Malawi 1509 
(1143 to 1970)
4·3 
(–15·0 to 27·7)
24 419 
(20 280 to 29 218)
–3·4 
(–6·9 to 0·0)
20 730 
(15 694 to 26 556)
1·9 
(–16·2 to 22·4)
Mozambique 2554 
(1995 to 3300)
–2·6 
(–16·4 to 14·8)
41 436 
(34 782 to 49 571)
–4·0 
(–7·4 to –0·7)
34 956 
(27 433 to 44 059)
–4·1 
(–16·8 to 11·5)
Rwanda 1004 
(799 to 1259)
16·2 
(1·5 to 31·9)
15 536 
(13 147 to 18 296)
–4·1 
(–7·5 to –0·3)
12 682 
(10 253 to 15 694)
11·0 
(–2·2 to 25·7)
Somalia 680 
(536 to 864)
–0·4 
(–10·0 to 12·5)
12 957 
(10 830 to 15 461)
–5·2 
(–8·7 to –1·7)
10 031 
(7993 to 12 698)
–1·7 
(–11·2 to 10·3)
(Table continues on next page)
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and diet high in sugar-sweetened beverages as risk factors 
for dementia. For each of these risk factors we set a 
theoretical minimum exposure level (TMREL) at which 
the risk of health outcomes is lowest. The TMREL was set 
to greater than 20 and less than 25 kg/m² for BMI; greater 
than 4·5 and less than 5·4 mmol/L for high fasting plasma 
glucose; zero for smoking; and less than 5g/day for sugar-
sweetened beverages.
Criteria for inclusion as a risk factor in GBD included 
sufficient evidence of a causal relationship, availability of 
exposure data, and potential for modification.14 Although 
physical inactivity and absence of education were not 
assessed for inclusion as risk factors for dementia in GBD 
2016, these will be considered in upcoming rounds. We 
calculated population-attributable fractions based on 
relative risk data, exposure data, and a theoretical mini-
mum level of exposure. When aggregating risks, we 
assumed a multiplicative function and accounted for 
instances where one risk was mediated through another. 
Additional details on risk factor calculations are in the 
GBD 2016 risk factor overview paper.14
Compilation of results
Years of life lost (YLLs) were calculated by multiplying the 
reference life expectancy at each age, taken from the GBD 
reference life table, by the number of deaths in each age 
group.28 Disability-adjusted life years (DALYs) were then 
calculated as the sum of YLLs and YLDs. Age-standardised 
rates were calculated using the GBD world popula-
tion standard.29 Uncertainty was propagated through all 
calculations by sampling 1000 draws at each step of the 
calculations, which enabled us to carry through uncertainty 
from multiple sources, including input data, corrections 
of measurement error, and estimates of residual non-
sampling error. 95% uncertainty intervals (95% UI) were 
defined as the 25th and 975th values of the ordered draws. 
Any report on signi ficant differences was based on the 
95% UI of the difference not including zero.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between 1990 and 2016, the number of prevalent 
dementia cases increased by 117% (95% UI 114–121), 
from 20·2 million (17·4–23·5) in 1990 to 43·8 million 
(37·8–51·0) in 2016, whereas there was an increase 
of only 1·7% (95% UI 1·0–2·4) in age-standardised 
prevalence, from 701 (602–815) per 100 000 population in 
1990 to 712 (614–828) per 100 000 population in 2016. 
Deaths (95% UI) Prevalence (95% UI) DALYs (95% UI)
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
South Sudan 881 
(677 to 1138)
10·2 
(–6·9 to 28·6)
18 205 
(15 254 to 21 613)
–4·9 
(–8·5 to –1·6)
13 002 
(10 053 to 16 543)
7·0 
(–8·2 to 24·7)
Tanzania 4728 
(3807 to 5909)
–0·2 
(–12·9 to 12·4)
74 748 
(63 715 to 87 463)
–5·9 
(–10·0 to –2·2)
63 516 
(50 730 to 78 312)
–1·6 
(–13·1 to 9·9)
Uganda 2531 
(2015 to 3154)
2·4 
(–9·4 to 15·3)
42 050 
(35 224 to 50 418)
–4·2 
(–7·4 to –0·6)
33 609 
(27 179 to 41 603)
–0·2 
(–10·6 to 11·0)
Zambia 1222 
(907 to 1609)
6·2 
(–15·1 to 30·3)
20 323 
(16 876 to 24 320)
–2·5 
(–6·1 to 1·2)
17 098 
(12 886 to 22 139)
4·7 
(–15·4 to 27·2)
Central sub-Saharan Africa 10 351 
(8 428 to 12 697)
8·1 
(0·2 to 17·5)
210 389 
(176 711 to 249 382)
–2·5 
(–4·9 to 0·0)
154 408 
(126 081 to 187 843)
5·6 
(–1·1 to 13·1)
Angola 1795 
(1354 to 2336)
23·7 
(1·2 to 57·1)
36 872 
(30 732 to 43 858)
–3·1 
(–6·6 to 0·3)
27 363 
(20 993 to 35 154)
15·4 
(–3·8 to 40·7)
Central African Republic 557 
(418 to 722)
2·9 
(–13·0 to 17·9)
12 817 
(10 652 to 15 123)
3·4 
(–2·2 to 12·0)
8538 
(6627 to 10 751)
4·2 
(–10·7 to 19·6)
Congo (Brazzaville) 594 
(477 to 725)
10·7 
(–5·4 to 27·6)
11 239 
(9653 to 12 938)
2·3 
(–4·4 to 9·3)
8551 
(6924 to 10 410)
7·9 
(–7·4 to 23·7)
Democratic Republic of the 
Congo
6905 
(5626 to 8637)
4·8 
(–3·7 to 15·4)
141 576 
(118 678 to 168 958)
–3·4 
(–6·8 to 0·5)
103 557 
(83 985 to 127 321)
3·3 
(–4·1 to 11·8)
Equatorial Guinea 93 
(60 to 131)
11·8 
(–20·1 to 46·6)
1716 
(1452 to 2015)
–4·4 
(–8·4 to –0·8)
1267 
(847 to 1769)
4·0 
(–22·7 to 33·2)
Gabon 407 
(326 to 504)
10·0 
(–5·0 to 26·1)
6170 
(5123 to 7355)
–2·0 
(–5·3 to 1·8)
5132 
(4121 to 6334)
6·6 
(–6·7 to 21·4)
Data are n (95% UI) or percentage change in age-standardised rates (95%UI). DALYs= disability-adjusted life-years. SDI=Socio-demographic Index. UI=uncertainty interval.
Table: Deaths, prevalence, and DALYs for Alzheimer’s disease and other dementias in 2016, and percentage change of age-standardised rates by location, 1990–2016
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For all-age prevalence over the same period, there 
was an increase of 54·7% (95% UI 52·1–57·5), from 
383 (330–447) per 100 000 population in 1990 to 593 
(511–690) per 100 000 population in 2016. The percentage 
change from 1990 to 2016 in age-standardised prevalence 
was highest for the high-middle SDI quintile (table). 
Age-standardised prevalence varied by a factor of three 
across countries in 2016. Turkey had the highest age-
standardised prevalence (1192 [95% UI 1007–1405] cases 
per 100 000 population), followed by Brazil (1037, 882–1220). 
Nigeria (397, 335–462) and Ghana (406, 342–483) had the 
lowest age-standardised prevalence estimates (figure 1).
The number of deaths due to dementia increased by 
148% (140–157) between 1990 and 2016. Globally in 2016, 
dementia was the fifth-largest cause of death (2·4 million 
[95% UI 2·1–2·8] deaths) after ischaemic heart disease, 
chronic obstructive pulmonary disease, intracerebral 
haemorrhage, and ischaemic stroke. In 2016, deaths due 
to dementia accounted for 4·4% (95% UI 3·8–5·1) of 
total deaths but 8·6% (7·4–10·1) of deaths in individuals 
aged more than 70 years (2·2 million [1·9–2·6] deaths),13 
making dementia the second largest cause of death in 
this age group after ischaemic heart disease. Globally, 
dementia caused 28·8 million (24·5–34·0) DALYs, 
making it the 23rd largest cause of DALYs globally in 
2016, up from 41st in 1990.16 Dementia accounted for 
1·2% (95% UI 1·0–1·4) of DALYs across all ages. Over 
the age of 70 years, this increased to 6·3% (5·4–7·5) of 
DALYs (23·9 million DALYs, 20·1–28·6).16
More women than men died from dementia in 2016 
(1·5 million, 95% UI 1·3–1·8 vs 0·8 million, 0·7–1·0). 
The age-standardised death rates in women were also 
higher than in men, in line with a higher prevalence in 
women than in men, indicating the female predominance 
was not simply due to the longer lifespan of women. 
Age-standardised global prevalence in females was 
1·17 times (1·17–1·18) the age-standardised prevalence in 
males in 2016, with more women globally affected by 
dementia (27·0 million, 95% UI 23·3–31·4) than men 
(16·8 million, 14·4–19·6).
Both YLLs and YLDs increased sharply with age 
(figure 2). However, YLL rates increased faster with age 
and were much higher than YLD rates at the oldest ages. 
Prevalence also increased substantially with age in both 
men and women, approximately doubling every 5 years 
between the ages of 50 and 80 years, after which the 
increase slowed owing to the high prevalence in the 
oldest ages (figure 3).
There was no clear pattern between age-standardised 
DALY rates for the 21 GBD world regions and SDI over 
the 1990–2016 estimation period (figure 4). At each SDI 
level, there was a large amount of heterogeneity between 
DALY rates due to dementia. There was no uniformity 
between regions in the changes over time in DALY rates, 
Figure 1: Age-standardised prevalence for Alzheimer’s disease and other dementias per 100 000 population by location for both sexes, 2016
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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with some regions increasing and others decreasing over 
the 1990–2016 period.
Overall, 6·4 million (95% UI 3·4–10·5) DALYs (22·3% 
[95% UI 11·8–35·1] of DALYs due to dementia) in 2016 
could be attributed to risk factors analysed as part of 
GBD: 3·5 million (1·4–6·7) DALYs (12·2% [4·7–23·1]) 
were attributed to high BMI; 2·1 million (0·4–4·9) 
DALYs (7·4% [1·6–16·1]) to high fasting plasma glucose; 
1·3 million (0·6–2·0) DALYS (4·4% [2·0–6·7]) to 
smoking; and 18·9 thousand (7·8–34·1) DALYs (0·07% 
[0·03–0·12]) to a diet high in sugar-sweetened beverages. 
There was no significant difference in the proportion of 
all dementia DALYs in 2016 explained by risk factors in 
men (24·7%, 12·7–37·6) compared with women (20·8%, 
8·6–35·7). More detailed estimates, including values for 
all years from 1990–2016, and all locations, all age groups, 
and both sexes, can be found in our online results tool.
Discussion
We estimated that in 2016, 27·0 million (95% UI 
23·3–31·4) women and 16·8 million (14·4–19·6) men 
lived with dementia in the 195 countries and territories 
that were included in the 2016 round of GBD. The number 
of prevalent cases of dementia more than doubled from 
1990 to 2016, contrasting with relatively minor changes in 
age-standardised prevalence and pointing to population 
ageing and growth as the main drivers of the increase. 
The numbers of DALYs and age-standardised DALY 
rates showed similar patterns to the prevalence figures. 
Dementia was the fifth leading cause of cause of death 
in 2016.
Our overall global estimate of 43·8 million people 
living with dementia in 2016 is close to the estimate in 
the World Alzheimer Report 2015 of 46·8 million for 
2015.2 Additionally, the GBD estimate of a doubling in 
number of prevalent cases and a 148% (140–157) increase 
in dementia deaths over the 26-year period from 1990 to 
2016 is of the same order as the doubling time of 20 years 
previously reported.2,3 However, the previous studies 
reported results only at the region level and did not 
use data across regions to generate estimates for all 
countries.
The increase in the number of cases of dementia is of 
even more importance given that there is currently no 
effective disease-modifying cure or treatment for the 
disease.30 Additionally, even when clinical trials are 
initiated, many more end in failure than success in 
bringing a new disease-modifying drug to market, with 
ratios of more than 100:1 compared with the 14·6:1 
pharmaceutical industry average.31,32 Without potential 
treatments, increasing numbers of cases will pose un-
due burden on individuals who have dementia, their 
caregivers, and health-care systems more generally.
In GBD 2016, only four risk factors were judged to have 
sufficient evidence for a causal link to Alzheimer’s disease 
and other dementias: high BMI, high fasting plasma 
glucose, smoking, and high intake of sugar-sweetened 
beverages.23 In GBD, the effect of high intake of sugar-
sweetened beverages was posited to be mediated through 
BMI on the basis of scientific literature linking BMI with 
dementia, but sugar-sweetened beverages as such ex-
plained only a negligible fraction of dementia burden 
attributed to risks. GBD is continuously reviewing new 
evidence for risk-outcome pairs and will update estimates 
of dementia burden attributable to risks in upcoming 
cycles for risk factors that meet GBD criteria for causality. 
For detailed estimates see 
http://ghdx.healthdata.org/gbd-
results-tool
Figure 2: Global  years lived with disability (YLDs) and years of life lost (YLLs) rates per 100 000 population 
due to Alzheimer’s disease and other dementias by age, 2016
Values are plotted at the midpoint of 5-year age categories. Shaded areas show 95% uncertainty intervals. 
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Figure 3: Global age-standardised prevalence of Alzheimer’s disease and other dementias by sex, 2016
Prevalence expressed as the percentage of the population that was affected by the disease. Values are plotted at 
the midpoint of 5-year age categories. Shading indicates 95% uncertainty intervals.
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A Lancet Commission Report5 suggested that modifiable 
risk factors including hearing loss, education, smoking, 
depression, physical inactivity, social isolation, diabetes, 
and obesity could account for as much as 35% of dementia 
burden. In the context of our finding of a doubling of the 
prevalence of this terminal disease every 5 years over age 
50 years, and the absence of a cure, the impetus to 
examine risk factors is clear.
Furthermore, the timing of interventions and pre-
vention efforts focused on modifiable risk factors for 
dementia warrants further investigation. The prodrome 
of disease is thought to be long, with evidence point ing 
to a length of 20–30 years, but potentially longer.33 
The inability to identify individuals accurately in the 
prodromal stage complicates the study of risk factors. 
Efforts to explore the timing of risk factors during this 
period are further limited by the span of observational 
studies and the short length of randomised controlled 
trials, as well as uncertainty over whether exposures are 
causative, are bystanders of highly correlated factors, or 
are even early symptoms of disease. Because of these 
issues, there are so far no official international lifestyle 
guidelines for preventing dementia.34 However, attention 
on the effects of dementia risks is increasing, and WHO 
has created a group tasked with the development of risk-
reduction guidelines.35
By 2050, the number of people living with dementia 
could be around 100 million.36 Tackling this will require 
training of health professionals, as well as planning and 
building facilities to cater to increasing numbers in-
dividuals with dementia. The cost of care for those living 
with dementia is also very high, especially in high-income 
countries. According to recent estimates, in the USA the 
cost was US$818 million in 2015, an increase of 35% since 
2010.37 Since ageing is expected to continue, the only way to 
reduce burden and associated costs is to identify effective 
preventive or treatment measures. Despite the low return 
on research investment in dementia in the past, the size 
of the burden and its increasing trend warrant a con-
tinued effort to find effective means of intervening. Until 
such breakthroughs are made, dementia will constitute 
an increasing challenge to health-care systems across 
the globe.
There were several limitations, separate from the broader 
limitations of GBD, relevant to the modelling process for 
dementia. First, to correct for changes in coding practices 
in cause of death data, we selected the countries that were 
most willing to code to dementia as a cause of death per 
prevalent case, and we assumed that certification and 
coding practices in these countries are correct. Although 
coding practices are probably not perfect in these countries, 
we selected them as the best available benchmark. Second, 
in this correction we then assumed that the excess 
mortality derived from these countries applied to all 
countries across the entire timeseries. Although this 
assumption was clearly approximate, it was necessary to 
address the changes in coding practices that led to large 
changes over the study period in cause of death data from 
countries with high-quality vital registration. Third, in 
correcting for the bias in cause of death data, we relied on 
prevalence data to determine patterns in geographical 
distribution of both prevalence and mortality. Although we 
had a large number of data sources from western Europe, 
east Asia, high-income Asia-Pacific, and high-income 
North America, for 13 of the 21 regions we had fewer than 
five prevalence sources. Fourth, there was a large amount 
of heterogeneity in the ways in which dementia was 
diagnosed within the available data. Of the 237 avail-
able data sources, 230 different diagnostic procedures 
were used.
Figure 4: Age-standardised disability-adjusted-life-year (DALY)rates for Alzheimer’s disease and other dementias by 
Socio-demographic Index (SDI), 1990–2016
The black line represents expected values of age-standardised DALY rates for each value of SDI.
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Although most of the data ultimately classified demen-
tia cases using the DSM or ICD definitions, differences 
between different versions of the DSM criteria could have 
led to differences in prevalence estimates, as suggested in 
a meta-regression analysis of prevalence studies in China.38 
Even if the same screening test was used, different studies 
often used different cutoff scores. For example, although 
42% of studies used the Mini-Mental State Examination in 
the screening phase, the absolute cutoff scores that were 
used ranged from 18 to 28, and other studies used different 
cutoff scores by educational attainment level. In this round 
of GBD we did not find a way to correct for such bias 
because of the extreme variability in methods, so it is likely 
that part of the observed variation in prevalence was due to 
measure ment bias rather than reflecting true geographical 
variation.
A potential next step in the GBD is to consider dividing 
dementia into subtypes, as these might have different 
epidemiological features and potentially different pre-
vention and treatment strategies. A first subdivision 
could be Alzheimer’s disease dementia, vascular de-
mentia, and remaining types. The challenges of sub-
dividing include sparse data and the complication of how 
to handle mixed types of dementia.39 However, increased 
use of biomarkers in the classification of dementia and 
Alzheimer’s disease might help facilitate subdivision.40,41 
Additionally, the data on severity distribu tions over age 
rely on few data sources and can be strengthened. We also 
aim to expand our data coverage through increased use of 
claims data and other data types, including general 
practitioner data, which have been used to estimate 
dementia prevalence.42–44
Monitoring trends in dementia is difficult because of 
the extreme variation in cause of death coding pract-
ices and the large heterogeneity in case-ascertainment 
methods. Although previous guidelines have been de-
veloped to systematise the reporting of neurological 
disorders generally, because of the diagnostic challenges 
noted with dementia, disease-specific guidelines are 
warranted and resources should be directed towards 
creating and implementing more systematic methods.45 
The GBD study will continue to update its estimates for 
dementia annually, and estimates might become more 
robust if data collection methods improve. Additionally, as 
new data become available on risk factors for dementia 
that meet GBD criteria for causal links, they can be 
incorporated into future iterations of GBD.
GBD 2016 Alzheimer’s disease and other dementia Collaborators
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